The ARON-1 Study is designed as an International Multicentric Retrospective Study to collect global experiences with the use of immuno-combinations in patients with metastatic RCC. Two Supplementary Studies (ARON-1α and ARON-1β) have been designed. The ARON-1α Supplementary Study has been designed to investigate for the presence of genomic signatures from tumor samples of patients treated with first-line immuno-combinations for advanced RCC. The ARON-1β Supplementary Study has been designed to charaterize the immune cell populations and assess their relationship with the clinical outcome of mRCC patients treated with first-line immuno-combinations
Study Type
OBSERVATIONAL
Enrollment
1,220
collect global experiences with the use of immuno-combinations in patients with metastatic RCC
Ospedale di Macerata, UOC Oncologia
Macerata, Macerata, Italy
RECRUITINGProgression-Free Survival (PFS)
Time frame: March 31th, 2022
Overall Survival (OS)
Time frame: March 31th, 2022
Overall Response Rate (ORR)
Time frame: March 31th, 2022
Efficacy of immuno-combination in the elderly populaton
Data on tumor assessment and response to therapy on elderly populaton will be statistically analyzed
Time frame: May 31th, 2022
Efficacy of immuno-combinations in patients with different metastatic sites (i.e. bone and brain metastases)
Data on tumor assessment and response to therapy will be statistically analyzed
Time frame: May 31th, 2022
Prognostic role of smoking attitude and obesity in RCC patients treated with different immuno-combinations
Statistical analysis of prognostic role of smoking attitude and obesity in treated RCC patients
Time frame: May 31th, 2022
Efficacy of different immuno-combinations in patients with non-clear RCC
Data on tumor assessment and response to therapy in non-clear RCC will be statistically analyzed
Time frame: September 30th, 2022
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.